Helmut Oettle

12.5k total citations · 3 hit papers
149 papers, 8.2k citations indexed

About

Helmut Oettle is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Helmut Oettle has authored 149 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 111 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 38 papers in Surgery. Recurrent topics in Helmut Oettle's work include Pancreatic and Hepatic Oncology Research (82 papers), Cancer Genomics and Diagnostics (35 papers) and Colorectal Cancer Treatments and Studies (28 papers). Helmut Oettle is often cited by papers focused on Pancreatic and Hepatic Oncology Research (82 papers), Cancer Genomics and Diagnostics (35 papers) and Colorectal Cancer Treatments and Studies (28 papers). Helmut Oettle collaborates with scholars based in Germany, United States and Spain. Helmut Oettle's co-authors include Hanno Riess, P. Neuhaus, Klaus Gellert, Karsten Ridwelski, Marco Niedergethmann, Uwe Pelzer, Jens Stieler, M. Arning, Bernd Dörken and Marianne Sinn and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

Helmut Oettle

146 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer

2007 1.8k citations Helmut Oettle, P. Neuhaus et al. profile →
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer

2013 1.3k citations Helmut Oettle, P. Neuhaus et al. profile →
Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer

2004 616 citations Helmut Oettle, Walter L. Vervenne et al. profile →

Peers

Countries citing papers authored by Helmut Oettle

Since Specialization

Citations

This map shows the geographic impact of Helmut Oettle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helmut Oettle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helmut Oettle more than expected).

Fields of papers citing papers by Helmut Oettle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helmut Oettle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helmut Oettle. The network helps show where Helmut Oettle may publish in the future.

Co-authorship network of co-authors of Helmut Oettle

This figure shows the co-authorship network connecting the top 25 collaborators of Helmut Oettle. A scholar is included among the top collaborators of Helmut Oettle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helmut Oettle. Helmut Oettle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial 2024 ·The Lancet. Gastroenterology & hepatology ·Klara Dorman, Stefan Boeck, Karel Caca, Maximilian Reichert, Thomas J. Ettrich, Helmut Oettle, Oliver Waidmann, Dominik Paul Modest, Lothar Müller, Patrick Michl, Stephan Kanzler, Daniel Pink, Anke Reinacher‐Schick, Michael Geißler, (unknown), Volker Kunzmann, Swantje Held, (unknown), Volker Heinemann, Frank Kullmann	2
2	Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for non-resectable locally advanced pancreatic cancer: First results of the CONKO-007 trial 2023 ·Zeitschrift für Gastroenterologie ·Robert Grützmann, Michael Ghadimi, Waldemar Uhl, Uwe A. Wittel, Wolf O. Bechstein, A. Reinacher-Schick, Andrea Tannapfel, Helmut Oettle, Rainer Fietkau	0
3	Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma 2018 ·British Journal of Cancer ·Philipp Lohneis, Marianne Sinn, Fritz Klein, Sven Bischoff, Jana K. Striefler, (unknown), Bruno V. Sinn, Uwe Pelzer, Helmut Oettle, Hanno Riess, Carsten Denkert, Hendrik Bläker, (unknown)	33
4	TP53 mutation predicts sensitivity to adjuvant gemcitabine in pancreatic cancer: Results from the CONKO-001 study 2017 ·Annals of Oncology ·M. Sinn, Jan Budczies, Frédérik Damm, Philipp Lohneis, Rosa Schmuck, Denise Treue, Jana K. Striefler, Marcus Bahra, Uwe Pelzer, (unknown), Hendrik Bläker, Sven Bischoff, Helmut Oettle, Carsten Denkert, Hanno Riess, (unknown)	3
5	Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine 2015 ·Oncology Research and Treatment ·Arndt Vogel, Frank Kullmann, Volker Kunzmann, Salah‐Eddin Al‐Batran, Helmut Oettle, Ruben R. Plentz, Jens T. Siveke, Christoph Springfeld, Hanno Riess	18
6	Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedside 2014 ·Cancer Treatment Reviews ·Helmut Oettle	79
7	First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group 2011 ·Cancer Chemotherapy and Pharmacology ·Uwe Pelzer, Dirk Arnold, P Reitzig, (unknown), F.W. Korsten, Manfred Kindler, Jens Stieler, Bernd Dörken, Hanno Riess, Helmut Oettle	5
8	Adjuvant therapy of pancreatic cancer 2010 ·Expert Review of Anticancer Therapy ·Andreas Hilbig, Helmut Oettle	4
9	Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the Pancreas 2009 ·The Cancer Journal ·Muhammad Wasif Saif, Helmut Oettle, Walter L. Vervenne, James P. Thomas, Gary Spitzer, Carla Visseren‐Grul, Nathan Enas, Donald Richards	44
10	Diagnostik und Therapie von Lebermetastasen bei kolorektalem Primärtumor 2009 ·Onkologie ·Dirk Arnold, Ernst J. Rummeny, Thomas Kirchner, Karsten Ridwelski, Helmut Oettle, (unknown), Markus Moehler, (unknown), Hauke Lang, Hans J. Schlitt, P. Neuhaus	1
11	Therapie des fortgeschrittenen Pankreaskarzinoms 2008 ·Onkologie ·(unknown), Ludger Staib, Helmut Oettle	1
12	Adjuvant Therapy in Pancreatic Cancer 2007 ·Drugs ·Helmut Oettle, P. Neuhaus	58
13	Gemcitabine in the Treatment of Advanced Head and Neck Cancer 2005 ·Clinical Oncology ·J.D. Raguse, Hans Joachim Gath, J. Bier, Hanno Riess, Helmut Oettle	19
14	Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer 2002 ·Cancer ·Helmut Oettle, Hanno Riess	33
15	Epidemiologie und interventionelle Therapiestrategien infektiöser Komplikationen nach allogener Stammzelltransplantation 2001 ·DMW - Deutsche Medizinische Wochenschrift ·Hermann Einsele, Hartmut Bertz, J. Beyer, (unknown), Volker Runde, H. J. Kolb, Ernst Holler, Rose Beck, (unknown), U. Schumacher, Holger Hebart, (unknown), J Kienast, (unknown), Georg Maschmeyer, William Krüger, Hartmut Link, (unknown), Helmut Oettle, (unknown)	5
16	Presence of human β- and γ-herpes virus DNA in Hodgkin’s disease 2000 ·Leukemia Research ·Christian Schmidt, Helmut Oettle, (unknown), (unknown), Freimut Wilborn, D. Huhn, W. Siegert, Hermann Herbst	12
17	Elevated reticulocyte count – a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report 1999 ·British Journal of Cancer ·Stefan Serke, Hanno Riess, Helmut Oettle, D. Huhn	20
18	Phase I trial of gemcitabine (Gemzar®), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer 1999 ·Anti-Cancer Drugs ·Helmut Oettle, Uwe Pelzer, (unknown), Thomas Diebold, Jan M. Langrehr, Christian Schmidt, M. Arning, Thomas J. Vogl, P. Neuhaus, D. Huhn, Hanno Riess	24
19	Demonstration of cytomegalovirus after bone marrow transplantation by polymerase chain reaction, virus culture and antigen detection in buffy coat leukocytes. 1994 ·PubMed ·(unknown), Helmut Oettle, Freimut Wilborn, Jason R. Jessen, H. Timm, Rainer Schwerdtfeger, Joachim Oertel, W. Siegert	27
20	Heterogeneity of V52 TCR 8 Gene Rearrangements in Acute Myeloid Leukemia 1994 ·Leukemia & lymphoma ·Christian A. Schmidt, Grzegorz K. Przybylski, Helmut Oettle, (unknown), Wolfgang Ludwig, W. Siegert	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact